Polypeptide pertussis toxin vaccine

Details Polypeptide pertussis toxin vaccine Polypeptide pertussis toxin vaccine

1988-08-02

1991-03-19

Springer, David B.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

530327, 4352525, A61K 3910

Patent

active

050009524

ABSTRACT:
A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and T-cells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individually or in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e.g., B. pertussis, for use as a vaccine to the intact organism.

REFERENCES:
patent: 4338299 (1982-07-01), Vesselinova et al.
patent: 4857318 (1989-08-01), Lee
Steinman et al., CA 113(5) Abst. No. 38746n, (1989).
Oksenberg et al., J. Immunol., 143(12), pp. 4227-4231, (1989).
DeMagistris et al., J. Exp. Med., 169(5), pp. 1519-1532, (1989).

Affiliated with

Also associated with

Rating

Polypeptide pertussis toxin vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptide pertussis toxin vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide pertussis toxin vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2008973